tailor-made methotrexate treatment in juvenile idiopathic arthritis PDF
Preview tailor-made methotrexate treatment in juvenile idiopathic arthritis
TAILOR-MADE METHOTREXATE TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS: AN ESTABLISHED DRUG REVISITED Maja Bulatović Ćalasan ISBN: 978-94-6108-620-4 © Maja Bulatović Ćalasan, 2014 The copyrights of the articles that have been published or accepted for publication have been transferred to the respective journals All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without prior permission of the author Layout and printing: Gildeprint, Enschede Cover design: Patrik Hurtig, [email protected] Photography: Mongolia and United States of America (Nevada, Death Valley) Printing of this thesis has been supported by the Dutch Arthritis Foundation, Infection & Immunity Utrecht, Medac GmbH, ABBVIE B.V., Pfizer B.V. and Roche B.V. TAILOR-MADE METHOTREXATE TREATMENT IN JUVENILE IDIOPATHIC ARTHRITIS: AN ESTABLISHED DRUG REVISITED METHOTREXAAT BEHANDELING OP MAAT BIJ JEUGDREUMA: EEN NIEUWE KIJK OP EEN BEKEND MEDICIJN (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 1 april 2014 des middags te 4.15 uur door Maja Bulatović Ćalasan geboren op 17 december 1982 te Podgorica, Montenegro Promotoren: Prof.dr. A.B.J. Prakken Prof.dr. N.M. Wulffraat Co-promotoren: Dr. R. de Jonge Dr. F. van Wijk Dit proefschrift werd mede mogelijk gemaakt met financiële steun van Medac GmbH, het Reumafonds en een NWO Mozaïek beurs toegekend aan M. Bulatović Ćalasan. Za moje roditelje For my parents CONTENTS Chapter 1 General introduction 9 Chapter 2 Translational medicine from bedside to bench and back again – 23 methotrexate revisited PART I Methotrexate treatment response Chapter 3 ABCB1 and ABCC3 gene polymorphisms are associated with first-year 55 response to methotrexate in juvenile idiopathic arthritis Chapter 4 Prediction of clinical non-response to methotrexate treatment in 73 juvenile idiopathic arthritis Chapter 5 Methotrexate polyglutamates in erythrocytes are associated with low 89 disease activity in juvenile idiopathic arthritis patients Chapter 6 Interpretation of the Juvenile Arthritis Disease Activity Score: 105 responsiveness, clinically important difference and levels of disease activity in a prospective cohort of patients with juvenile idiopathic arthritis PART II Methotrexate intolerance Chapter 7 High prevalence of methotrexate intolerance in juvenile idiopathic 121 arthritis: development and validation of a methotrexate intolerance severity score Chapter 8 Prevalence of methotrexate intolerance in rheumatoid and psoriatic 137 arthritis Chapter 9 Effect of oral methotrexate (MTX) and behavioural therapy or 151 parenteral MTX versus oral MTX and antiemetics on MTX intolerance in juvenile idiopathic arthritis: a randomised controlled trial Chapter 10 Prediction of methotrexate intolerance in juvenile idiopathic arthritis 167 PART III Methotrexate effects on T cells Chapter 11 Methotrexate treatment affects effector, but not regulatory T cells in 187 juvenile idiopathic arthritis Chapter 12 General discussion 211 Addendum 1 Do snapshot statistics fool us in MTX pharmacogenetic studies in 233 arthritis research? Addendum 2 Summary 241 Samenvatting 245 Acknowledgments 247 Curriculum vitae 253 List of publications 255 1 GENERAL INTRODUCTION R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 R19 R20 R21 R22 R23 R24 R25 R26 R27 R28 R29 R30 R31 R32 R33 R34 R35 R36 R37 R38 R39 10 General introduction
Description:The list of books you might like
